Cystine stones account for only about 1% to 2% of all kidney stones but represent about 6% to 8% of all pediatric calculi. The name "cystine" comes from its original description as "bladder calculi" in 1833.
Kidney stones are the primary clinical manifestation of this condition. The primary treatment is optimization of urinary volume and pH with hydration and oral alkalinizing drugs. Medical therapy consists of thiol-based drugs and is used in patients where conservative measures alone are insufficient.
While most cystine stone formers will make pure cystine stones, up to 40% may develop mixed calculi that will also contain calcium oxalate, calcium phosphate, or struvite.
Compared to calcium stone formers, cystine nephrolithiasis patients will tend to make larger stones, require more urological procedures and will start making stones at an earlier age. They also face a greater risk of eventual kidney damage and chronic renal failure compared to calcium nephrolithiasis patients.
The cause of cystinuria is an inheritable, autosomal recessive genetic defect that affects the proximal renal tubular reabsorption of cystine. This same problem also affects lysine, ornithine, and arginine (COLA) but only cystine is clinically significant as it is the only amino acid in this group that will form stones. Cystine is the least soluble of all the essential amino acids. Interestingly, intestinal transport and absorption of cystine, in patients with cystinuria, tends to be impaired, but other factors offset this benefit. 
Cystinuria would not be a problem except for its relative insolubility in urine at physiological pH levels. Cystine solubility is highly pH-dependent because it substantially increases as the urine becomes increasingly alkaline.
Cystine solubility is also affected by urinary macromolecules and ions, both of which increase cystine's solubility.
Worldwide and United States incidence is about 1 in 7000 population. Prevalence is 1/100,000 in Sweden, 1/18,000 in Japan, 1/40,00 in Australia, 1/2500 in Israel, and 1/2000 in Great Britain and Spain. In cystinuric stone formers, the typical patient makes about one stone every 1 to 2 years, has one surgical procedure every 3 years, and has undergone 7 surgeries by the time they are middle-aged.
The solubility of cystine in urine is about 250 mg/L at a pH of 6.5. This solubility increases as the urine becomes more alkaline. For example, 500 mg of cystine will dissolve in a liter of urine at a pH of 7.5. This solubility goes up to 750 mg/L at a pH of 8, but it becomes very difficult to achieve a pH above 7.5 in clinical practice, and there is also an increased risk of calcium phosphate precipitation in very alkaline urine.
Initial presentation of a patient with cystine stones is identical to any patient with obstructing urolithiasis. They typically will develop acute flank pain with hematuria often associated with nausea and vomiting. The pain will radiate around the flank towards the groin, and they often have CVA tenderness. Microscopic or gross hematuria is frequently present, but up to 15% of patients with obstructing stones may not have even microscopic hematuria. The strongest element in the history is a strong personal or family history of cystinuria and cystine stone formation.
Since cystine contains sulfur, the urine of hyper-cystinuric individuals may have a rotten egg odor. Typical hexagonal cystine crystals can sometimes be seen on urinalysis in affected patients. When these hexagonal crystals are seen on urinalysis, it suggests supersaturation of the urine with cystine.
The sodium cyanide-nitroprusside test is often the initial laboratory screening test for cystinuria as it is fast, simple and provides a reliable, qualitative assessment of urinary cystine levels. The cyanide converts cystine to cysteine which then binds to the nitroprusside creating an intense purple color in just a few minutes. The test typically turns positive at cystine levels above 75 mg/gm creatinine.
The definitive diagnosis of obstructing calculi will require imaging which includes CT scans, KUB x-rays and/or ultrasound. CT scans without contrast remain the "gold standard" for the diagnosis of urolithiasis and will demonstrate cystine stones clearly as will an ultrasound for renal calculi, but they cannot distinguish cystine from other stone chemical constituents. Plain x-rays of the abdomen will not show cystine stones well as they are only faintly radiopaque and will tend to have a ground glass appearance.
Surgical treatment of cystine stones is similar to that of other stones except that cystine is notoriously resistant to extracorporeal shock wave lithotripsy (ESWL) unless the stones are less than 1 cm in size. Retrograde pyelography and the use of indwelling ureteral catheters will help to visualize stones that otherwise would be difficult to localize for ESWL therapy. Even then, the stones are relatively difficult to see and target reliably. They also will likely require more shocks than calcium oxalate or calcium phosphate stones. For these reasons, ureteroscopy with laser lithotripsy is preferred for most cystinuria patients with obstructing cystine stones that require surgery.
Total removal of all cystine stones and fragments has demonstrated reduced recurrence rates and better preservation of renal function. Surgery has not caused any measurable decrease in overall renal function. 
Acceptable levels of urinary cystine are 250 mg/L or less at a urinary pH of 6.5 to 7. This level can often be reached through an increased fluid intake and urinary alkalinization. The use of thiol-based medications to reduce urinary cystine levels is discouraged unless hydration therapy and alkalinization treatment are insufficient to achieve the desired "optimal" cystine concentration levels (less than 250 mg/L) at an acceptable pH (6.5 to 7). A sustained urinary pH of 7.5 can be used to dissolve existing cystine stones. Some experts have recommended even lower cystine concentrations of 150 mg/L and possibly even lower at 90 mg/L as "optimal."
Hydration is usually the first step in medical management. Increasing fluid intake sufficiently to reliably generate 2500 to 3000 ml or more of urine per day is often necessary. The goal is to dilute the urine sufficiently to get the urinary cystine content as close to the less than 250 mg/L recommended concentration level as possible. This frequently requires having the patient wake up in the middle of the night to void and drink extra water. Drinking 240 ml of water every hour during the day and 480 ml before bed and at least once overnight is a standard strategy for maximizing oral hydration. Hydration can be monitored by following the specific gravity which should always be 1.010 or less. Since some cystinuric patients can generate up to 1400 mg of cystine per day, hydration alone may not be sufficient, but it is always the first step in management. Up to one-third of cystine stone patients can manage their stone recurrences with fluid management. Optimal hydration will depend on the patient's cystine excretion.
Alkalinization can not only prevent cystine precipitation and stone formation but may also dissolve existing cystine stones. For prophylaxis, the urinary pH should be targeted at 7.0 to 7.5, but for stone dissolution, a urinary pH higher than 7.5 needs to be maintained. At this high pH level (above 7.5), calcium phosphate stones can precipitate. In such cases, hypercalciuria needs to be controlled tightly with diet and thiazides. Mineral water and citrus juices can help increase pH levels, but potassium citrate supplementation is the mainstay of urinary alkalinization therapy. Usual daily potassium citrate dosage in cystinuria is 60 to 90 mEq total in 3 or 4 divided doses and then titrated as needed to optimize the pH. Serum potassium should also be checked periodically in patients on high dosages of potassium citrate to detect hyperkalemia.
Sodium bicarbonate can also be used to help with pH issues, but it tends to have a relatively short-term alkalinizing effect, and the extra sodium intake may increase urinary cystine excretion. High animal protein diets are also discouraged in cystinuric patients for the same reason.
Acetazolamide is a carbonic anhydrase inhibitor that increases urinary bicarbonate excretion and raises urinary pH levels. While not a first-line therapy (it can cause hypocitraturia and metabolic acidosis), it may occasionally be of some help in maintaining high urinary pH levels in addition to the other therapies mentioned. It can be particularly useful in maintaining a high overnight urinary pH without the need for multiple awakenings or additional overnight alkalinization dosing.
When conservative measures as outlined above are insufficient after a 3-month trial period, a thiol-based drug regimen is usually the next step in active cystine stone formers.
Cystine is composed of 2 cysteine molecules bound together by a disulfide bond. Thiol-based drugs have sulfhydryl groups that can reduce this disulfide bond producing a mixed cysteine disulfide compound that is far more soluble than the original cystine molecule. As a general guide, most patients with a 24-hour urinary cystine excretion of 500 mg or more are likely to need a thiol medication in addition to hydration therapy and alkalinization.
Thiol-based treatment is thought to have the extra benefit of possibly making cystine stones more amenable to ESWL treatment. This may occur because of the mixing of calcium phosphate along with the cystine creating a more fragile stone that is more easily fragmented with ESWL therapy.
Penicillamine, a penicillin derivative, was the first thiol drug used for cystinuria. Penicillamine-cysteine disulfide is 50 times more soluble in urine than cystine. Each 250 mg penicillamine tablet can reduce urinary cystine levels by about 75 mg to 100 mg per day. The problem with penicillamine is that there is a high incidence of side effects including fever, rash, loss of taste, arthritis, leukopenia, aplastic anemia, gastrointestinal (GI) disturbances, renal membranous nephropathy with proteinuria, and pyridoxine deficiency. The incidence of significant side effects is about 50% which limits long-term compliance. Almost 70% of patients discontinued the drug due to adverse effects in one study. For these reasons, penicillamine use is limited in favor of other thiol-based drugs.
Tiopronin (Thiola, alpha-mercaptopropionylglycine, or alpha-MPG) is a second-generation thiol drug that works similarly to penicillamine but is roughly 30% more effective with significantly fewer side effects. It was approved for use in the United States in 1988, so there is ample experience with the medication. The typical dose is 300 mg three times per day. Long-term compliance is about 70%. For these reasons, tiopronin is currently the thiol drug of choice for cystinuria when hydration and urinary alkalinization therapy fail to achieve optimal cystine concentration levels at an acceptable pH.
Captopril is an ACE inhibitor normally used for hypertension, but it is also a thiol-based drug that can form captopril-cysteine mixed disulfides that are highly soluble, in cystinuric patients. While safe with few side effects, captopril's clinical effectiveness in cystinuric stone forming patients is uncertain as various studies provide conflicting results. It should be considered a reasonable treatment option in cystinuric patients who are also hypertensive.
Bucillamine is a third-generation, thiol-based drug that is currently available only in Japan and South Korea and is approved only for use in rheumatoid arthritis. As a di-thiol compound, it would theoretically be more effective than tiopronin and better tolerated since lower dosages of the drug would be needed. Experience in Asia has shown a low toxicity profile, and phase-2 studies are currently underway in the United States to determine its potential clinical usefulness in treating hyper cystinuria.
Besides Bucillamine, other new cystine binding agents or crystal growth inhibitors are being evaluated. For example, L-cystine dimethyl esters (L-CDME) and L-cystine methyl esters (L-CME) have shown promising results with good therapeutic effects at relatively low concentrations which suggest better tolerability and fewer side effects than similar agents.  Some new, investigational thiol compounds, such as thiophosphate and meso-2-3-dimercaptosuccinic acid, are undergoing testing and appear promising.
Most urinary dipsticks do not have any clear color differentiation between pH of 6 and 7.5. A small Indianapolis company, Urodynamics (317-915-7896, 317-257-1302), makes an FDA-approved dipstick for home and patient use that has such differentiation as well as a specific gravity reading that is ideal for urine pH and hydration monitoring in cystine stone forming patients on medical therapy.
Experimentally, real-time in situ atomic force microscopy has shown that L-cystine dimethyl ester (L-CDME) and L-cystine methyl ester (L-CME) can dramatically reduce the growth rate of cystine stones and crystals. They interfere with specific receptor sites on crystal surfaces that block cystine molecule binding. 
Stem cell transplants have shown positive activity in reducing cystinuria in the mouse model.
Crystal growth inhibitors may be the next new wave of prophylactic treatments for cystine stone patients.
About 25% of cystine stone formers will have non-cystine chemical components in their stones. For this reason, complete stone composition analyses and 24 hour urine tests are recommended for optimal stone prophylaxis.
an interprofessional team should work toward educating patients that treatment for cystinuria starts with diet (low meat protein, low sodium) and hydration sufficient to generate 2500 to 3000 mL of urine daily or more. Urinary alkalinization with mineral water, fruit juices, and potassium citrate will greatly increase cystine solubility. The goal is to achieve a cystine concentration of 250 mg/L or less at a pH of at least 6.5. "Optimal" cystine level is generally considered to be 150 mg/L or less, but some reports suggest that a cystine concentration goal of 90 mg/L is "optimal." If this is not achievable or possible for any reason, (tolerability, compliance issues, side effects), then the use of a thiol-based cystine lowering medication is warranted. Currently, tiopronin (Thiola) is the recommended thiol medication of choice based on its efficacy and reduced side effect profile.
The interprofessional team of urology nurses and clinicians should educate patients that long term studies of cystinuria patients followed for 21 years has shown that the best preservation of renal function and the lowest recurrence rates are found in those with early medical management of cystinuria along with complete surgical stone removal. [Level V]
|||Reinstatler L,Stern K,Batter H,Scotland KB,Ardekani GS,Rivera M,Chew BH,Eisner B,Krambeck AE,Monga M,Pais VM Jr, Conversion from Cystine to Noncystine Stones: Incidence and Associated Factors. The Journal of urology. 2018 Dec; [PubMed PMID: 30059686]|
|||Yang Y,Albanyan H,Lee S,Aloysius H,Liang JJ,Kholodovych V,Sahota A,Hu L, Design, synthesis, and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuria. Bioorganic [PubMed PMID: 29571572]|
|||Usawachintachit M,Sherer B,Hudnall M,Tzou DT,Taguchi K,Hsi RS,Stoller M,Chi T, Clinical Outcomes for Cystinuria Patients with Unilateral Versus Bilateral Cystine Stone Disease. Journal of endourology. 2018 Feb; [PubMed PMID: 29179563]|
|||Friedlander JI,Antonelli JA,Canvasser NE,Morgan MSC,Mollengarden D,Best S,Pearle MS, Do Urinary Cystine Parameters Predict Clinical Stone Activity? The Journal of urology. 2018 Feb; [PubMed PMID: 28916274]|
|||Shen L,Cong X,Zhang X,Wang N,Zhou P,Xu Y,Zhu Q,Gu X, Clinical and genetic characterization of Chinese pediatric cystine stone patients. Journal of pediatric urology. 2017 Dec; [PubMed PMID: 28689648]|
|||Gres AA,Nitkin DM,Juraha TM,Sivakow AA, [Cystine as a risk factor of the stone formation in kidney: the reference value range of urinary excretion, the stage diagnosis of cystine metabolism disorder]. Urologiia (Moscow, Russia : 1999). 2016 Aug; [PubMed PMID: 28247719]|
|||Streeper NM,Wertheim ML,Nakada SY,Penniston KL, Cystine Stone Formers Have Impaired Health-Related Quality of Life Compared with Noncystine Stone Formers: A Case-Referent Study Piloting the Wisconsin Stone Quality of Life Questionnaire Among Patients with Cystine Stones. Journal of endourology. 2017 Apr; [PubMed PMID: 27717296]|
|||Obaid A,Nashabat M,Al Fakeeh K,Al Qahtani AT,Alfadhel M, Delineation of cystinuria in Saudi Arabia: A case series. BMC nephrology. 2017 Feb 6; [PubMed PMID: 28166740]|
|||Andreassen KH,Pedersen KV,Osther SS,Jung HU,Lildal SK,Osther PJ, How should patients with cystine stone disease be evaluated and treated in the twenty-first century? Urolithiasis. 2016 Feb; [PubMed PMID: 26614112]|
|||Courbebaisse M,Prot-Bertoye C,Bertocchio JP,Baron S,Maruani G,Briand S,Daudon M,Houillier P, [Nephrolithiasis of adult: From mechanisms to preventive medical treatment]. La Revue de medecine interne. 2017 Jan; [PubMed PMID: 27349612]|
|||Nakagawa Y,Coe FL, A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. Clinica chimica acta; international journal of clinical chemistry. 1999 Nov; [PubMed PMID: 10556653]|
|||Nakanishi Y,Hanasaki T,Yo T,Shiraishi Y,Togo Y,Taoka R,Suzuki T,Higuchi Y,Kanematsu A,Hashimoto T,Doi Y,Nojima M,Yamamoto S, [Impacted ureteral stents with cystine encrustation in cystinuric patients : report of two cases]. Hinyokika kiyo. Acta urologica Japonica. 2013 Oct; [PubMed PMID: 24262706]|
|||Rousaud F,Gracia S,Palacín M,Nunes V,Millán F,Oliver A,Rousaud A, [Cystinuria and cystine kidney lithiasis. Diagnosis and therapeutic approach]. Archivos espanoles de urologia. 2001 Nov; [PubMed PMID: 11789376]|
|||Moore SL,Somani BK,Cook P, Journey of a cystinuric patient with a long-term follow-up from a medical stone clinic: necessity to be SaFER (stone and fragments entirely removed). Urolithiasis. 2019 Apr; [PubMed PMID: 29696300]|
|||Sterrett SP,Penniston KL,Wolf JS Jr,Nakada SY, Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology. 2008 Aug; [PubMed PMID: 18533229]|
|||Joly D,Rieu P,Méjean A,Gagnadoux MF,Daudon M,Jungers P, Treatment of cystinuria. Pediatric nephrology (Berlin, Germany). 1999 Nov; [PubMed PMID: 10603157]|
|||Fattah H,Hambaroush Y,Goldfarb DS, Cystine nephrolithiasis. Translational andrology and urology. 2014 Sep 1; [PubMed PMID: 25383320]|
|||Cohen TD,Streem SB,Hall P, Clinical effect of captopril on the formation and growth of cystine calculi. The Journal of urology. 1995 Jul; [PubMed PMID: 7776415]|
|||Hu L,Yang Y,Aloysius H,Albanyan H,Yang M,Liang JJ,Yu A,Shtukenberg A,Poloni LN,Kholodovych V,Tischfield JA,Goldfarb DS,Ward MD,Sahota A, l-Cystine Diamides as l-Cystine Crystallization Inhibitors for Cystinuria. Journal of medicinal chemistry. 2016 Aug 11; [PubMed PMID: 27409142]|
|||Sahota A,Tischfield JA,Goldfarb DS,Ward MD,Hu L, Cystinuria: genetic aspects, mouse models, and a new approach to therapy. Urolithiasis. 2019 Feb; [PubMed PMID: 30515543]|
|||Sfoungaristos S,Hakim R,Katz R,Gofrit ON,Landau EH,Yutkin V,Pode D,Duvdevani M, Cystine stones: a single tertiary center experience. Journal of endourology. 2015 Mar; [PubMed PMID: 25133928]|